Companion Diagnostics Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Companion diagnostics are medical devices that provide information essential for the safe and effective use of corresponding therapeutic products, typically identifying biomarkers that predict patient response to specific drugs. The market has grown significantly in recent years, with the 2025 valuation at $8.69 billion reflecting strong demand for personalized medicine solutions. These diagnostics are most commonly associated with oncology treatments, where they help match patients with targeted cancer therapies based on genetic or protein markers.

• •Tests are developed alongside therapeutic drugs and often required by regulators before drug approval
• •Oncology applications dominate the market, particularly for lung, breast, and colorectal cancers
• •The market encompasses various technologies including immunohistochemistry, PCR, next-generation sequencing, and in situ hybridization

The rising global incidence of cancer and other complex diseases is a primary catalyst, as healthcare systems increasingly prioritize treatments tailored to individual genetic profiles. Regulatory agencies including the FDA and EMA have established pathways that encourage co-development of drugs and diagnostics, reducing time to market for companion test-therapy combinations. Additionally, advances in genomic sequencing technologies have lowered costs and expanded the range of detectable biomarkers, making companion diagnostics more accessible across broader patient populations.

• •Growing emphasis on personalized medicine and precision oncology by healthcare providers and payers
• •Increasing number of targeted therapies in clinical development requiring companion diagnostic approval
• •Technological improvements in molecular diagnostics enabling detection of novel biomarkers

The market is segmented by technology, product type, indication area, and drug class, with immunohistochemistry and polymerase chain reaction representing the most established diagnostic technologies. North America currently holds the largest market share due to advanced healthcare infrastructure, high adoption of precision medicine, and strong pharmaceutical R&D activity. However, the Asia-Pacific region is expected to witness the fastest growth, driven by rising cancer incidence, improving healthcare access, and increasing investments in biotechnology.

• •Immunohistochemistry and PCR technologies account for the largest technology segment, while next-generation sequencing is growing rapidly
• •Oncology indications represent the dominant application area, with breast, lung, and colorectal cancers being key focus segments
• •North America leads regional demand, with Europe and Asia-Pacific following as important growth markets

What are the recent trends and outlook?

The market is moving toward broader companion diagnostic approaches that identify multiple biomarkers simultaneously, supporting combination therapies and complex treatment algorithms. Liquid biopsy technologies, which enable non-invasive detection of circulating tumor DNA, are emerging as a significant trend that could expand the reach of companion diagnostics beyond traditional tissue-based testing. As regulatory science evolves, there is growing momentum for comprehensive genomic profiling tests that can match patients to multiple approved therapies, potentially shifting the market from single-biomarker tests toward multiplex diagnostic solutions.

• •Liquid biopsy and next-generation sequencing technologies are enabling more comprehensive genomic profiling approaches
• •Regulatory pathways are evolving to accommodate biomarker-agnostic drug approvals tied to companion diagnostics
• •The market is expected to consolidate around $15-17 billion by the early 2030s, with oncology remaining the primary growth driver